Luseogliflozin

  • 1 lab in 1 country
  • Funder: Taisho Toyama Pharmaceutical Company
  • Human trial1
  • Humans1

Outcomes

2

Liver stiffness

downin humans1

1 study
  1. Luseogliflozin decreases liver stiffness in humans.

    Human trialadded to semaglutide in type 2 diabetes and MASHliver52 weeks

    Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial

    Diabetes, obesity & metabolism17 Aug 2026

More on Liver stiffness

MASH resolution without worsening fibrosis

no changein humans1

1 study
  1. Luseogliflozin has no effect on MASH resolution without worsening fibrosis in humans (34.9% vs 19.4%).

    Human trialadded to semaglutide in type 2 diabetes and MASHliver52 weeks

    Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial

    Diabetes, obesity & metabolism17 Aug 2026

Latest

Nov 2025: 0Dec 2025: 1Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 1Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 03 in 12 months